Literature DB >> 20836773

Incremental benefit of 80-lead electrocardiogram body surface mapping over the 12-lead electrocardiogram in the detection of acute coronary syndromes in patients without ST-elevation myocardial infarction: Results from the Optimal Cardiovascular Diagnostic Evaluation Enabling Faster Treatment of Myocardial Infarction (OCCULT MI) trial.

Brian J O'Neil1, James Hoekstra, Yuri B Pride, Cedric Lefebvre, Deborah Diercks, W Frank Peacock, Gregory J Fermann, C Michael Gibson, Duane Pinto, James F Giglio, Abhinav Chandra, Charles B Cairns, Carol Clark, Joe Massaro, Mitchell Krucoff.   

Abstract

BACKGROUND: The initial 12-lead (12L) electrocardiogram (ECG) has low sensitivity to detect myocardial infarction (MI) and acute coronary syndromes (ACS) in the emergency department (ED). Yet, early therapies in these patients have been shown to improve outcomes.
OBJECTIVES: The Optimal Cardiovascular Diagnostic Evaluation Enabling Faster Treatment of Myocardial Infarction (OCCULT-MI) trial was a multicenter trial comparing a novel 80-lead mapping system (80L) to standard 12L ECG in patients with chest pain and presumed ACS. This secondary analysis analyzed the incremental value of the 80L over the 12L in the detection of high-risk ECG abnormalities (ST-segment elevation or ST depression) in patients with MI and ACS, after eliminating all patients diagnosed with ST-elevation MI (STEMI) by 12L ECG.
METHODS: Chest pain patients presenting to one of 12 academic EDs were diagnosed and treated according to the standard care of that site and its clinicians; the clinicians were blinded to 80L results. MI was defined by discharge diagnosis of non-ST-elevation MI (NSTEMI) or unstable angina (UA) with an elevated troponin. ACS was defined as discharge diagnosis of NSTEMI or UA with at least one positive test result (troponin, stress test, angiogram) or revascularization procedure.
RESULTS: Of the 1,830 patients enrolled in the trial, 91 patients with physician-diagnosed STEMI and 225 patients with missing 80L or 12L data were eliminated from the analysis; no discharge diagnosis was available for one additional patient. Of the remaining 1,513 patients, 408 had ACS, 206 had MI, and one had missing status. The sensitivity of the 80L was significantly higher than that of the 12L for detecting MI (19.4% vs. 10.4%, p = 0.0014) and ACS (12.3% vs. 7.1%, p = 0.0025). Specificities remained high for both tests, but were somewhat lower for 80L than for 12L for detecting both MI and ACS. Negative and positive likelihood ratios (LR) were not statistically different between groups. In patients with severe disease (defined by stenosis > 70% at catheterization, percutaneous coronary intervention, coronary artery bypass graft, or death from any cause), the 80L had significantly higher sensitivity for detecting MI (with equivalent specificity), but not ACS.
CONCLUSIONS: Among patients without ST elevation on the 12L ECG, the 80L body surface mapping technology detects more patients with MI or ACS than the 12L, while maintaining a high degree of specificity. 2010 by the Society for Academic Emergency Medicine

Entities:  

Mesh:

Year:  2010        PMID: 20836773     DOI: 10.1111/j.1553-2712.2010.00848.x

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  3 in total

1.  QRS Complex Detection and Measurement Algorithms for Multichannel ECGs in Cardiac Resynchronization Therapy Patients.

Authors:  Antonia E Curtin; Kevin V Burns; Alan J Bank; Theoden I Netoff
Journal:  IEEE J Transl Eng Health Med       Date:  2018-06-05       Impact factor: 3.316

2.  Association between obesity and ECG variables in children and adolescents: A cross-sectional study.

Authors:  Guo-Zhe Sun; Yang Li; Xing-Hu Zhou; Xiao-Fan Guo; Xin-Gang Zhang; Li-Qiang Zheng; Yuan Li; Yun-DI Jiao; Ying-Xian Sun
Journal:  Exp Ther Med       Date:  2013-10-09       Impact factor: 2.447

3.  Construction of an Electrocardiogram Database Including 12 Lead Waveforms.

Authors:  Dahee Chung; Junggu Choi; Jong-Hwan Jang; Tae Young Kim; JungHyun Byun; Hojun Park; Hong-Seok Lim; Rae Woong Park; Dukyong Yoon
Journal:  Healthc Inform Res       Date:  2018-07-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.